CN103800661A - Composition for improving immunity and relieving physical fatigue and preparation thereof - Google Patents
Composition for improving immunity and relieving physical fatigue and preparation thereof Download PDFInfo
- Publication number
- CN103800661A CN103800661A CN201410012306.9A CN201410012306A CN103800661A CN 103800661 A CN103800661 A CN 103800661A CN 201410012306 A CN201410012306 A CN 201410012306A CN 103800661 A CN103800661 A CN 103800661A
- Authority
- CN
- China
- Prior art keywords
- extract
- compositions
- group
- ganoderma
- fructus lycii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a composition for improving immunity and relieving physical fatigue and a preparation thereof. The composition comprises the following components: cervus elaphus linnaeus, wolfberry extract, dwarf lilyturf root tuber extract, ganoderma extract and American ginseng extract. Experiments indicate that the composition is non-toxic, and has the functions of improving immunity and relieving physical fatigue.
Description
Technical field
The present invention relates to field of health care food, is the compositions of a kind of enhancing immunity, alleviating physical fatigue and containing its preparation specifically.
Background technology
Immunity is that body is identified and gets rid of antigenicity foreign body, safeguards the physiological equilibrium of self and stable a kind of function, i.e. defence, certainly steady and supervision three large functions.The immunologic function of body is to produce in long-term biological evolution process.Immunne response is carried out in body immune system, and immune system is made up of immune organ, immunocyte and immune molecule, is respectively to be carried out by innate immunity (nonspecific immunity) and acquired immunity (specific immunity).Wherein acquired immunity is completed by cellular immunity and body fluid immunity close fit.Therefore, improve immunity and resisting fatigue and also become the focus of growing interest, exploitation just has vast meaning take enhancing immunity and alleviating physical fatigue as the health food of function.
Patient or immunologic hypofunction suffers virus infraction, or dysimmunity produces irritated allergy, or immunologic derangement produces autoimmune.Modern medicine is in the mechanism and diagnosis of above-mentioned disease, and there is a profound understanding and various detection meanss, but in the treatment of disease, still stay in " primary stage ", and the adjustment to immunologic function and recovery lack effective means and medicine.Many patients have no alternative but to rely on hormone to subsist, because prolonged application hormone side effect layer goes out constantly, has endless trouble.
Ancients are early recognized pertinacious disease obstinate disease, and " immunity " word has elaboration all through the ages in traditional Chinese medical science ancient books.As its name suggests, immunity exempts the evil of epidemic disease.The traditional Chinese medical science is thought: " persistent ailment is expectorant ", expectorant is the next scorching word of disease prefix, it is the common trait of above-mentioned persistent ailment that dysimmunity causes ill inflammation.Therefore Chinese medicine method in treatment immune disease is a lot of, and curative effect is rather good.For example some heat and toxic materials clearing away medicine energy antiviral and infection, some drug for invigorating blood circulation and eliminating stasis energy antiallergic and elimination allergy, the immunologic function of some medicine energy enhancing body of tonifying Qi of the kidney, some Chinese medicine can also be two-ways regulation to immunity, make T lymphocytosis, bone-marrow-derived lymphocyte reduces, and some Chinese medicine can also regulate and control complement and various lymphokine.In a word, grasp Chinese and western medical science theory, flexible Application Chinese medicine, on the stubborn disease of the various dysimmunities for the treatment of, often can obtain than simple western medicine and treat better effect.
About the compositions of enhancing immunity, there are a lot of reports:
CN201010532968.0(publication number is CN102465073A) a kind of Fig health care wine disclosed, the compositions of utilizing the compositions such as Fructus Fici, Fructus Jujubae, Fructus Lycii, cervus elaphus linnaeus, Radix Ginseng, Herba Epimedii, Ganoderma, Mel, the party has the effect of enhancing immunity.
CN201110138602.X(publication number is CN102204995A) a kind of Traditional Chinese medicinal health-care wine of invigrating kidney disclosed, formed by cervus elaphus linnaeus 0.4-0.5 gram, Radix Ginseng 25.0-30.0 gram, Ganoderma 14.0-15.0 gram, Herba Epimedii 20.0-22.0 gram, Poria 4.0-5.0 gram, Fructus Lycii 25.0-30.0 gram, medical material.
At present, there is not yet the novel composing prescription of cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract composition.
Summary of the invention
The object of this invention is to provide the compositions of a kind of enhancing immunity, alleviating physical fatigue.
The compositions of a kind of enhancing immunity provided by the invention, alleviating physical fatigue, it contains following composition: cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract.
Concrete, the composition that described compositions contains following weight portion: cervus elaphus linnaeus 1-4 part, Fructus Lycii extract 0.5-3 part, Radix Ophiopogonis extract 0.5-2 part, Ganoderma extract 0.5-2 part, Radix Panacis Quinquefolii extract 0.5-1.5 part.
Preferably, the composition that described compositions contains following weight portion: cervus elaphus linnaeus 1.1-3.3 part, Fructus Lycii extract 0.8-2.4 part, Radix Ophiopogonis extract 0.6-1.8 part, Ganoderma extract 0.55-1.65 part, Radix Panacis Quinquefolii extract 0.5-1.5 part.
Further preferably, the composition that described compositions contains following weight portion: 2.2 parts of cervus elaphus linnaeuss, 1.6 parts of Fructus Lycii extracts, 1.2 parts of Radix Ophiopogonis extracts, 1.1 parts of Ganoderma extracts, 1 part of Radix Panacis Quinquefolii extract.
In above-mentioned composition:
Described weight portion can be the known unit of weights of field of medicaments such as μ g, mg, g, kg, can be also its multiple, as 1/10,1/100,10 times, 100 times etc.;
Described Fructus Lycii extract refers to the water extract of Fructus Lycii, and wherein the content of crude polysaccharides is no less than 30.0%;
Described Radix Ophiopogonis extract refers to the water extract of Radix Ophiopogonis, and the content of crude polysaccharides is no less than 3.0%;
Described Ganoderma extract refers to the water extract of Ganoderma, and the content of crude polysaccharides is no less than 10.0%;
Described Radix Panacis Quinquefolii extract refers to the ethanol extract of Radix Panacis Quinquefolii, and the content of total saponins is no less than 10.0%.
The present invention also provides the preparation containing above-mentioned composition, and said preparation is made up of compositions and pharmaceutically acceptable carrier.
Concrete, in described preparation: compositions 6-8 part and pharmaceutically acceptable carrier 0.5-5.2 part.
Preferably, in described preparation: compositions 6-8 part, microcrystalline Cellulose 0.9-2.7 part, magnesium stearate 0.04-0.12 part.
Further preferably, in described preparation: compositions 6-8 part, 1.8 parts of microcrystalline Cellulose, 0.08 part of magnesium stearate.
Described preparation is tablet, capsule, granule.
In described compositions or preparation, contain following effective ingredient composition: every 100g is containing crude polysaccharides 6.3g, total saponins 1.3g.
The present invention also provides the preparation method of above-mentioned preparation, and the method comprises the following steps: described each composition is sieved respectively, then take each composition according to proportioning, mix, be prepared into preparation according to conventional formulation method.
The present invention also provides above-mentioned composition or the application of preparation in medicine or the health product of preparing enhancing immunity, alleviating physical fatigue.
The compositions of enhancing immunity provided by the invention, alleviating physical fatigue has a little following:
1, product provided by the invention is natural health care, Therapeutic Principle according to Traditional Chinese medical theory to hypoimmunity and physical fatigue, and in conjunction with a large amount of function document and clinical literature, screen the raw material of Chinese medicine with enhancing immunity and alleviating physical fatigue, take cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract and Radix Panacis Quinquefolii extract as primary raw material.Wherein cervus elaphus linnaeus is returned liver, kidney channel, invigorating kidney-YANG, benefiting essence-blood, bone and muscle strengthening; Fructus Lycii is returned liver, kidney channel, can nourishing the liver and kidney, beneficial smart hemopoietic, improving eyesight; Radix Ophiopogonis GUIXIN, lung, stomach, can YIN nourishing and the production of body fluid promoting, lung moistening clears away heart-fire.Ganoderma GUIXIN, lung, liver, kidney channel, can invigorating QI and tranquilization, relieving cough and asthma; Radix Panacis Quinquefolii GUIXIN, lung, kidney channel, can boosting qi and nourishing yin, clearing away heat and promoting production of body fluid; All medicines share, can the liver and the kidney tonifying, lung moistening clears away heart-fire, invigorate vital energy and yang, replenishing YIN and removing heat, nourishing blood to tranquillize the mind.Hypoimmunity and physical fatigue patient QI and blood, the body fluid loss of hitting, the etiology and pathogenesis of visceral dysfunction, promotes that equilibrium between yin and yang, QI and blood are in harmonious proportion, function is coordinated, and reaches effect of alleviating physical fatigue and enhancing immunity.And effect is lasting, and raw material sources are extensive, reliable in quality, price material benefit.
2, this product is raw materials used is safe healthy food material, and production technology meets food hygiene related request, and therefore this product edible safety, without any side effects, can eat for a long time.
3, consumption aspect, this product is raw materials used is all Ministry of Public Health, State Food and Drug Administration approves spendable healthy food material, the mainly requirement with reference to the Pharmacopoeia of the People's Republic of China and relevant policies rules on consumption, it is mainly as treatment consumption that Chinese Pharmacopoeia is recorded consumption, should not serve as the function of health food and safe effective guarantee, and pharmacopeia consumption can be understood as single medicinal material consumption, and traditional tcm health preserving theory and the experience of the many utilizations of health food prescription, composite making, adding medicine is that short-term is used for the treatment of purposes, and health food is to select voluntarily for a long time to eat, therefore the consumption of each raw material is corresponding also can be on the low side.The each raw material of this product is without incompatibility.Each raw material consumption has also embodied its safer one side lower than pharmacopeia consumption.
4, show through experiment: compositions avirulence provided by the invention, there is the function of enhancing immunity, alleviating physical fatigue.
The specific embodiment
Following examples are used for illustrating the present invention, but are not used for limiting the scope of the invention.
Described Fructus Lycii extract refers to the water extract of Fructus Lycii, and wherein the content of crude polysaccharides is no less than 30.0%, purchased from Jia Kang source, Beijing development in science and technology company limited;
Described Radix Ophiopogonis extract refers to the water extract of Radix Ophiopogonis, and the content of crude polysaccharides is no less than 3.0%, purchased from Jia Kang source, Beijing development in science and technology company limited;
Described Ganoderma extract refers to the water extract of Ganoderma, and the content of crude polysaccharides is no less than 10.0%, purchased from Jia Kang source, Beijing development in science and technology company limited;
Described Radix Panacis Quinquefolii extract refers to the ethanol extract of Radix Panacis Quinquefolii, and the content of total saponins is no less than 10.0%, purchased from Jilin Hongjiu Biotech Co., Ltd..
Embodiment 1: the compositions of enhancing immunity, alleviating physical fatigue
1, formula: cervus elaphus linnaeus 55g, Fructus Lycii extract 120g, Radix Ophiopogonis extract 90g, Ganoderma extract 27.5g, Radix Panacis Quinquefolii extract 25g.
Adjuvant: microcrystalline Cellulose 182g, magnesium stearate 2g.
2, preparation method:
1) get the raw materials ready: cervus elaphus linnaeus adopts
60co roentgenization carries out irradiation sterilization (5KGy), for subsequent use;
2) pulverize, sieve: 80 mesh sieves are pulverized and crossed to the Universalpulverizer of the cervus elaphus linnaeus after irradiation sterilization, for subsequent use;
Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract, microcrystalline Cellulose, magnesium stearate are respectively at crossing 80 mesh sieves in vortex oscillation sieve, for subsequent use.
3) weigh, mix: take cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract, microcrystalline Cellulose, magnesium stearate by formula ratio, put in mixer and mix 30 minutes, mix homogeneously, obtains mixed powder.
4) fill capsule, select capsule, polishing, subpackage: mixed powder automatic hard capsule filler filled capsules.Adjusting and filling loading amount is 0.45g/ grain.After the polishing of medicine buffing machine, be distributed into plastic bottle in bottled production line;
5) outer package, product inspection and warehouse-in.
Embodiment 2: the compositions of enhancing immunity, alleviating physical fatigue
1, formula: cervus elaphus linnaeus 165g, Fructus Lycii extract 40g, Radix Ophiopogonis extract 30g, Ganoderma extract 82.5g, Radix Panacis Quinquefolii extract 75g.
Adjuvant: microcrystalline Cellulose 45g, magnesium stearate 6g.
2, preparation method:
1) get the raw materials ready: cervus elaphus linnaeus adopts
60co roentgenization carries out irradiation sterilization (5KGy), for subsequent use.
2) pulverize, sieve: 80 mesh sieves are pulverized and crossed to the Universalpulverizer of the cervus elaphus linnaeus after irradiation sterilization, for subsequent use.Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract, microcrystalline Cellulose, magnesium stearate are respectively at crossing 80 mesh sieves in vortex oscillation sieve, for subsequent use.
3) weigh, mix: take cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract, microcrystalline Cellulose, magnesium stearate by formula ratio, put in mixer and mix 30 minutes, mix homogeneously, obtains mixed powder;
4) fill capsule, select capsule, polishing, subpackage: mixed powder automatic hard capsule filler filled capsules.Adjusting and filling loading amount is 0.45g/ grain.After the polishing of medicine buffing machine, be distributed into plastic bottle in bottled production line;
5) outer package, product inspection and warehouse-in.
Embodiment 3: the compositions of enhancing immunity, alleviating physical fatigue
1, formula: cervus elaphus linnaeus 110g, Fructus Lycii extract 80g, Radix Ophiopogonis extract 60g, Ganoderma extract 55g, Radix Panacis Quinquefolii extract 50g.
Adjuvant: microcrystalline Cellulose 120g, sucrose 100g, PVP K30 20g, magnesium stearate 5g, coating powder 15g.
2, preparation method
1) get the raw materials ready: cervus elaphus linnaeus adopts
60co roentgenization carries out irradiation sterilization (5KGy), for subsequent use.
2) pulverize, sieve: 80 mesh sieves are pulverized and cross respectively to cervus elaphus linnaeus and sucrose with pulverizer, for subsequent use; Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract, microcrystalline Cellulose, magnesium stearate are respectively at crossing 80 mesh sieves in vortex oscillation sieve, for subsequent use;
3) weigh, mix: take cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract, microcrystalline Cellulose, sucrose, PVP K30, magnesium stearate, coating powder according to formula ratio respectively, cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract, microcrystalline Cellulose, sucrose are put in mixer and mixed 30 minutes, mix homogeneously, obtains mixed powder.
4) granulate, dry, granulate, always mixed: adding 95% ethanol to be made into concentration PVP K30 is 15%(volume ratio) PVP K30 alcoholic solution; and join in the mixed powder that step 3) obtains; soft material processed in wet granulator; soft material is granulated with 18 mesh sieves; obtain wet granular; wet granular is placed in to fluidized drying pelletizer dry (45～50 ℃ of temperature), then uses Fast granulate machine 16 mesh sieve granulate, obtain dry granule.Dry granule and magnesium stearate are placed in to mixer and mix 5 minutes, obtain always mixed granule.
5) tabletting: always mixed granule tablet machine tabletting, 0.6g/ sheet, obtains plain sheet.Check, reject defective.
6) coating: film coating procedure
Coating powder is slowly added in 70% ethanol preparing, stir, cross 100 mesh sieves for subsequent use.Solid-liquid w/v g:ml is 1:12.5.Open seed-coating machine, add plain sheet, be preheating to 40 ℃, adjustment rotating speed is 3-4 rev/min, and adjustable spraying amount is controlled air output, pressure and inlet temperature at any time, after thin film dress material has sprayed, continues dry 20-30 minute.Sheet dries in the air.Coating weightening finish 2-3%.Reject defective coated tablet;
7) inner packing: qualified coated tablet is proceeded to plastic bottle;
8) outer package, product inspection, warehouse-in.
Comparative example: compositions
Composition and preparation method, with reference to the embodiment 1 of CN201110138602.X, adopt the preparation method identical with embodiment 1, and it consists of:
Cervus elaphus linnaeus 0.48g, Radix Ginseng 28.80g, Ganoderma 14.40g, Herba Epimedii 21.60g, Poria 4.80g, Fructus Lycii 28.80g.
Experimental example 1: toxicological test
1, test objective: whether check product has toxicity.
2, test material:
The compositions that 2.1 samples: embodiment 1 provides, people intend with dosage be 1.8g/60kg.bw. day, institute's feeding sample is capsule 's content, for brown to the alternate powder of brown color.
2.2 laboratory animals: clean level ICR mice.
2.3 experimental situation conditions: 20 ℃～25 ℃ of temperature, humidity 40 ﹪～70 ﹪.
3, experimental technique: adopt the conventional test of chmice acute Oral toxicity, Salmonella reversion test, mouse marrow cell micro nuclear test, mouse sperm deformity to test to check product toxicity, specifically comprise following experimental procedure:
3.1 chmice acute Oral toxicity tests: select 20 of clean level Kunming mouses, body weight 18-22 gram, male and female half and half, test by MTD method (maximum tolerated dose).Take tested material 60g and add deionized water and mix to 160ml, adopt secondary gavage in equal-volume administration by gavage (0.2ml/10gbw) 24 hours, dosage is 20ml/kgbw.Continuous Observation two weeks, records poisoning manifestations and death condition;
3.2Ames test: adopt flat board to mix method, divide and add and do not add two kinds of S-9 mixed liquors.Dosage is respectively 0.008,0.040,0.200,1.000,5.000mg/ ware, separately establishes blank group, solvent control group (deionized water) and positive controls.
Tested material compound method is, takes tested material 2.5g and is dissolved in 50ml deionized water, and sterilizing in 0.103Mpa20 minute is stock solution; Getting stock solution 1ml, to add sterilizing deionized water 4ml be 1.000mg/ ware dosage; 5 times are diluted to other dosage successively.Getting each dosage group liquid 100 μ l adds in top layer culture medium.Positive controls is used 2-AF20 μ g/ ware, 2,4,7-TNFone0.5 μ g/ ware, NaN
32.5 μ g/ wares, ametycin 4.0 μ g/ wares, 1,8 dihydroxyanthraquinone 50 μ g/ wares, each dosage group is made three parallel wares, repeats to do twice.Bacterial strain is TA97(a), TA98, TA100 and TA102 tetra-strain bacterium, S-9 consumption be every ware 0.5mlS-9 mixed liquor (containing S-950 μ l).Bacterial strain is purchased from Tianjin Center for Disease Control and Prevention, and S-9 is purchased from Occupational Health and Poisoning Control Inst., China Disease Prevention and Co, and reagent is purchased from Beijing chemical reagents corporation;
3.3 mouse marrow cell micro nuclear tests: select 50 of clean level Kunming mouses, be divided at random five groups, 10 every group, male and female half and half; If three dosage group: 2.5g/kgbw, 5.0g/kgbw, 10.0g/kgbw.
Tested material compound method is: take tested material 2.5g, 5.0g, 10.0g and add respectively deionized water and mix to 80ml; Establish negative control group (deionized water) and positive controls (cyclophosphamide 200mg adds normal saline to 100ml, and dosage is 40mg/kgbw) simultaneously.Adopt equal-volume administration by gavage (0.2ml/10gbw), respectively organize 24 hours twice, equal interval provisions, within after provisions 6 hours for the second time, get bone marrow of sternum film-making, every animal 1000 polychromatic erythrocytes of counting (PCE), calculate its microkernel incidence; Count the mature erythrocyte (RBC) in 200 polychromatic erythrocyte visuals field, calculate PCE/RBC ratio
3.4 mouse sperm deformity test reports: select 25 of clean level Kunming kind mices, be divided at random five groups, five every group; If three dosage group: 2.5/5.0/10.0g/kgbw.
Tested material compound method is: take tested material 5.0,10.0,20.0g and add respectively deionized water and mix to 160ml; Establish negative control group (deionized water) and positive controls (cyclophosphamide 200mg adds normal saline to 100ml, and dosage is 40mg/kgbw) simultaneously.Adopt equal-volume administration by gavage (0.2ml/10gbw), continuously per os provisions 5 days, puts to death animal on the 35th day from provisions meter first, gets the film-making of bilateral epididymis, and 1000 sperms of every animal counting, calculate abnormal rate.
4, result of the test:
The compositions that 4.1 acute toxicities: embodiment 1 provides is all greater than 20.0g/kg body weight to female mice per os MTD, belongs to nontoxic level.
The compositions that 4.2 micronucleus tests: embodiment 1 provides is negative to PCEMNR micronucleus test testing result.
4.3Ames test: the compositions Salmonella reversion test testing result that embodiment 1 provides is negative.
4.4 mouse sperm deformity tests: the compositions that embodiment 1 provides is negative to mouse sperm deformity test testing result.
Result shows: compositions provided by the invention does not have toxicity.
Experimental example 2: enhancing immunity zoopery:
1, test material:
The compositions that 1.1 samples: embodiment 1 provides, people intend with dosage be 1.8g/60kgbw. day, institute's feeding sample is capsule 's content, for brown to brown color powder.
1.2 experimental animals: 192 of 18-22g female SPF mices.
1.3 dosage are selected to give mode with tested material: basic, normal, high three the dosage groups of embodiment 1 and matched group, be respectively the medicine 0.90g/kgBW that medicine 0.15g/kgBW, 0.30g/kgBW, 0.90g/kgBW and comparative example that embodiment 1 proportioning makes are made, wherein the consumption of embodiment 1 is equivalent to people and intends 5 times, 10 times, 30 times with dosage.Tested material is prepared with sterilized water, and per os gives once a day, and gavage was surveyed indices after 32 days continuously, and mouse stomach volume is that 0.1ml/10g Mus is heavy.Establish blank group (0g/kgBW) simultaneously, replace tested material with sterilized water, every day, gavage volume was identical with each tested material group.Each dosage group all gives normal feedstuff.
1.4 key instruments and reagent: electronic balance, spiral micrometer, microsyringe, 24 holes and 96 level land, hole Tissue Culture Plate plates, the 96 U-shaped Tissue Culture Plates in hole etc.
2, functional examination:
Delayed allergy: get Sanguis caprae seu ovis, normal saline washing 3 times, through the Sanguis caprae seu ovis of lumbar injection 2%, after injection, 24h measures left back sufficient sole of the foot portion thickness;
The mouse lymphocyte transformation experiment of ConA induction: the aseptic spleen of getting, grind with tweezers, make cell suspension, microscopy counting, cultivates colorimetric determination on spectrophotometer;
Antibody-producting cell detects: get Sanguis caprae seu ovis, and normal saline washing 3 times, every Mus, through lumbar injection 2%, is got spleen, grinds with tweezers, makes cell suspension, counting hemolysis plaque number;
The mensuration of half hemolysis value: get Sanguis caprae seu ovis, normal saline washing 3 times, every Mus, through lumbar injection 2%, is collected serum, measures optical density value;
Mice carbon is cleaned up experiment: the india ink by body weight from 4 times of mouse tail vein injection dilutions, with spectrophotometric determination;
Turnover of Mouse Peritoneal Macrophages is engulfed chicken red blood cell experiment: mouse peritoneal is injected 20% chicken red blood cell, calculates phagocytic rate and phagocytic index;
NK cytoactive: before experiment 24h by target cell cultivations of going down to posterity, at microplate reader photometry density value, calculating NK cytoactive.
3, result of the test:
3.1 impacts on mice delayed allergy (DTH): in table 1
Table 1: on the impact of mice delayed allergy (DTH)
| Group | Dosage | Number of animals (only) | Swelling degree of the paw (mm) |
| Blank group | 0g/kg·BW | 12 | 0.44±0.08 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 12 | 0.68±0.19 *# |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 12 | 0.70±0.23 *# |
| Embodiment 1 high dose group | 0.90g/kg·BW | 12 | 0.63±0.17 *# |
| Contrast groups | 0.90g/kg·BW | 12 | 0.45±0.09 |
Note: compared with blank group,
*p<0.05,
*p<0.01; Compared with contrast groups,
#p<0.05
Table 1 result shows: compared with blank group, per os gave compositions that the embodiment 1 of mice various dose provides after 32 days, the low dose group of embodiment 1 and middle dosage group swelling degree of the paw have significant difference (P<0.01), and high i.e. two groups of swelling degree of the paw have significant difference (P<0.05).With the comparison of comparative example group, the delayed allergy ability (P<0.05) of the raising mice that each group of embodiment 1 can be in various degree.
3.2 impacts on mouse lymphocyte transformation experiment: in table 2
Table 2: on the impact of mouse lymphocyte transformation experiment
| Group | Dosage | Number of animals (only) | Lymphopoiesis ability (OD difference) |
| Blank group | 0g/kg·BW | 12 | 0.26±0.08 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 12 | 0.29±0.06 |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 12 | 0.32±0.10 |
| Embodiment 1 high dose group | 0.90g/kg·BW | 12 | 0.37±0.10 *# |
| Contrast groups | 0.90g/kg·BW | 12 | 0.25±0.06 |
Note: compared with blank group,
*p<0.05,
*p<0.01; Compared with contrast groups,
#p<0.05
Table 2 result shows: per os gave compositions embodiment 1 medicine that the embodiment 1 of mice various dose provides after 32 days, high dose group and the comparison of blank group, and lymphopoiesis ability has significant difference (P<0.05).Be that embodiment 1 high dose group all can improve mouse lymphocyte multiplication capacity.
With the comparison of comparative example group, embodiment 1 high dose group of Isodose can improve mouse lymphocyte multiplication capacity.（P<0.05）
3.3 impacts on mouse antibodies cellulation number: in table 3
Table 3: on the impact of mouse antibodies cellulation number
| Group | Dosage | Number of animals (only) | Hemolysis plaque number (× 10 3/ full spleen) |
| Blank group | 0g/kg·BW | 12 | 190±100 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 12 | 297±200 |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 12 | 378±123 *# |
| Embodiment 1 high dose group | 0.90g/kg·BW | 12 | 354±200 *# |
| Contrast groups | 0.90g/kg·BW | 12 | 300±128 |
Note: compared with blank group,
*p<0.05,
*p<0.01; Compared with contrast groups,
#p<0.05
Table 3 result shows: per os gave compositions that the embodiment 1 of mice various dose provides after 32 days, and compared with blank group, middle dosage group and high dose group antibody-producting cell number have significant difference (P<0.05).The middle dosage group and the high dose group that are embodiment 1 all can improve mouse antibodies cellulation number.
With the comparison of comparative example group, embodiment 1 high dose group of Isodose can improve mouse antibodies cellulation number.（P<0.05）
3.4 impacts that mice carbon is cleaned up to ability: in table 4
Table 4: the impact of mice carbon being cleaned up to ability
| Group | Dosage | Number of animals (only) | Phagocytic index (a) |
| Blank group | 0g/kg·BW | 12 | 6.38±0.69 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 12 | 6.44±0.50 |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 12 | 6.84±0.81 *# |
| Embodiment 1 high dose group | 0.90g/kg·BW | 12 | 7.13±0.86 *# |
| Contrast groups | 0.90g/kg·BW | 12 | 6.40±0.68 |
Note: compared with blank group,
*p<0.05,
*p<0.01; Compared with contrast groups,
#p<0.05
Table 4 result shows: per os gave compositions that the embodiment 1 of mice various dose provides after 32 days, and compared with blank group, the carbon of middle dosage group and high dose group is cleaned up phagocytic index significant difference (P<0.05).Be that the carbon that the middle and high dosage group of embodiment 1 can improve mice is cleaned up ability.
With the comparison of comparative example group, embodiment 1 high dose group of Isodose can improve the carbon of mice and clean up ability.（P<0.05）
3.5 impacts that mouse macrophage is engulfed to chicken red blood cell phagocytic rate: in table 5
Table 5: the impact of mouse macrophage being engulfed to chicken red blood cell phagocytic rate
Note: compared with blank group,
*p<0.05,
*p<0.01; Compared with contrast groups,
#p<0.05
Table 5 result shows: per os gave compositions that the embodiment 1 of mice various dose provides after 32 days, and compared with blank group, the phagocytic rate that high dose group mouse macrophage is engulfed chicken red blood cell has significant difference (P<0.05).Be that embodiment 1 high dose group group all can improve mouse macrophage and engulfs chicken red blood cell phagocytic rate.
With the comparison of comparative example group, embodiment 1 high dose group of Isodose can improve mouse macrophage and engulf chicken red blood cell phagocytic rate.（P<0.05）
3.6 impacts that mouse macrophage is engulfed to chicken red blood cell phagocytic index: in table 6
Table 6: the impact of mouse macrophage being engulfed to chicken red blood cell phagocytic index
| Group | Dosage | Number of animals (only) | Phagocytic index |
| Blank group | 0g/kg·BW | 12 | 0.41±0.14 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 12 | 0.42±0.11 |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 12 | 0.47±0.10 |
| Embodiment 1 high dose group | 0.90g/kg·BW | 12 | 0.54±0.09 *# |
| Contrast groups | 0.90g/kg·BW | 12 | 0.45±0.12 |
Note: compared with blank group,
*p<0.05,
*p<0.01; Compared with contrast groups,
#p<0.05
Table 6 result shows: per os gave compositions that the embodiment 1 of mice various dose provides after 32 days, and compared with blank group, the macrophage phagocytic chicken red blood cell phagocytic index of high dose group mice has significant difference (P<0.05).Be that embodiment 1 high dose group can improve mouse macrophage and engulfs chicken red blood cell phagocytic index.
With the comparison of comparative example group, embodiment 1 high dose group of Isodose can improve mouse macrophage and engulf chicken red blood cell phagocytic index.（P<0.05）
Sum up: per os gave compositions that the embodiment 1 of mice various dose provides after 32 days, and with the comparison of blank group, this tested material low dose group can improve mice delayed allergy ability (P<0.01); Middle dosage group can improve mice mice delayed allergy ability (P<0.01), improves the antibody-producting cell number (P<0.05) of mice; High dose group group can improve mice delayed allergy ability (P<0.05), improve the lymphopoiesis ability (P<0.05) of mice, improve the antibody-producting cell number (P<0.05) of mice, improve the carbon of mice and clean up ability (P<0.05), improve mouse macrophage and engulf chicken red blood cell phagocytic rate (P<0.05) and phagocytic index (P<0.05).
In like manner, other embodiment and proportioning of the present invention tested, effect is with embodiment 1.
Result shows: tested material has no adverse effects to weight of mice.
According to " health food check and assessment technique standard " (2003 editions), known to the criterion of enhancing immunity health food, the function results of animal of compositions enhancing immunity provided by the invention is positive.
Experimental example 3: alleviating physical fatigue function:
1, test material:
The compositions that 1.1 samples: embodiment 1 provides, people intend with dosage be 1.8g/60kgbw. day, institute's feeding sample is capsule 's content, for brown to brown color powder.
204 of the male SPF level of 1.2 experimental animals: 18-22g mices.
1.3 dosage are selected to give mode with tested material: basic, normal, high three the dosage groups of embodiment 1, be respectively 0.15g/kgBW, 0.30g/kgBW, 0.90g/kgBW, and be equivalent to people and intend 5 times, 10 times, 30 times with dosage.Tested material is prepared with sterilized water, and per os gives once a day, and gavage was surveyed indices after 32 days continuously, and mouse stomach volume is that 0.1ml/10g Mus is heavy.Establish a blank group (0g/kgBW) simultaneously, replace tested material with sterilized water, every day, gavage volume was identical with each tested material group.Each dosage group all gives normal feedstuff.
1.4 key instruments and reagent: 755 spectrophotometers, Plasma lactate instrument, biochemistry analyzer, electronic balance, centrifuge, agitator, swimming trunk, galvanized wire, sample injector, homogenizer, test tube, tool plug test tube.
2, test method: functional examination
Test by swimming with a load attached to the body: the mice 5% body weight galvanized wire of loading is placed in swimming trunk went swimming, record mice and start to the dead time from swimming;
Serum urea: last to mice tested material after, swimming is pulled out eyeball blood sampling after having a rest, and in biochemistry analyzer, measures;
Hepatic glycogen: last to mice tested material after, immediately put to death, get liver filter paper after normal saline rinsing and blot, measure;
The mensuration of blood lactic acid: last to mice tested material after, blood sampling, swimming, has a rest, and measures with Plasma lactate instrument.
3, result of the test:
3.1 impacts on the mice burden swimming time: in table 7
Table 7: on the impact of mice burden swimming time
| Group | Dosage | Number of animals (only) | When swimming with a load attached to the body (min) |
| Blank group | 0g/kg·BW | 15 | 4.5±2.0 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 15 | 6.6±2.8 |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 15 | 7.0±3.0 |
| Embodiment 1 high dose group | 0.90g/kg·BW | 15 | 9.8±3.9 *# |
| Contrast groups | 0.90g/kg·BW | 15 | 7.5±2.6 |
Note: compared with blank group,
*p<0.05,
*p<0.01; Compared with contrast groups,
#p<0.05
From table 7, per os gave compositions that the embodiment 1 of mice various dose provides after 32 days, and with the comparison of blank group, there is significant difference (P < 0.01) the high dose group mice burden swimming time.Be that embodiment 1 high dose group group can extend the swimming with a load attached to the body time of mice.
With the comparison of comparative example group, there is significant difference (P < 0.01) the 1 high dose group swimming with a load attached to the body time of embodiment of Isodose.
3.2 impacts on the mice burden swimming time: in table 8
Table 8: on the impact of serum urea level after mice
| Group | Dosage | Number of animals (only) | Serum urea (mmol/) |
| Blank group | 0g/kg·BW | 12 | 17.7±2.3 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 12 | 16.6±2.4 |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 12 | 15.8±1.5 |
| Embodiment 1 high dose group | 0.90g/kg·BW | 12 | 15.4±1.8 *# |
| Contrast groups | 0.90g/kg·BW | 12 | 16.2±2.5 |
Note: compared with blank group,
*p<0.05,
*p<0.01; Compared with contrast groups,
#p<0.05
From table 8, per os gave compositions that the embodiment 1 of mice various dose provides after 32 days, and with the comparison of blank group, the serum urea content of high dose group mice has significant difference (P < 0.05).Be that embodiment 1 high dose group can reduce tired mice serum urea content.
With the comparison of comparative example group, the embodiment 1 high dose group serum urea content of Isodose has significant difference (P < 0.05).
3.3 impacts on the mice burden swimming time: in table 9
Table 9: on the impact of Mouse Liver glycogen content
| Group | Dosage | Number of animals (only) | Hepatic glycogen (mg/100g liver) |
| Blank group | 0g/kg·BW | 12 | 4879±913 |
| Embodiment 1 low dose group | 0.15g/kg·BW | 12 | 6383±616 *# |
| Dosage group in embodiment 1 | 0.30g/kg·BW | 12 | 6451±525 *# |
| Embodiment 1 high dose group | 0.90g/kg·BW | 12 | 4845±478 # |
| Contrast groups | 0.90g/kg·BW | 12 | 4915±547 |
Note: compared with blank group,
*p<0.05,
*p<0.01; Compared with contrast groups,
#p<0.05
Table 9 result shows: per os gave compositions that the embodiment 1 of mice various dose provides after 32 days, and compared with blank group, the hepatic glycogen content of low, middle dosage group mice has significant difference (P<0.01).Be that low, the middle dosage group of embodiment 1 can increase tired Mouse Liver glycogen content.
With the comparison of comparative example group, the embodiment 1 high dose group hepatic glycogen content of Isodose has significant difference (P<0.01).
3.4 impacts on the mice burden swimming time: in table 10
Table 10: on the impact of blood Lactate after mice swimming
Note: compared with blank group,
*p<0.05,
*p<0.01; Compared with contrast groups,
#p<0.05
Table 10 result shows: per os gave compositions that the embodiment 1 of mice various dose provides after 32 days, the comparison of blank group, and the blood lactic acid area under curve of high dose group mice has significant difference (P<0.01).Be that embodiment 1 high dose group can reduce the rear Mouse Blood lactic acid area under curve of swimming.
With the comparison of comparative example group, the embodiment 1 high dose group blood lactic acid area under curve of Isodose has significant difference (P < 0.01)
Experiment brief summary: per os gave compositions that the embodiment 1 of mice various dose provides after 32 days, and with the comparison of blank group, this tested material low dose group can improve Mouse Liver glycogen content (P < 0.01); Middle dosage group can improve Mouse Liver glycogen content (P < 0.01); High dose group can extend mice the swimming with a load attached to the body time (P < 0.01), reduce tired mice serum urea content (P < 0.05), can reduce swimming after Mouse Blood lactic acid area under curve (P < 0.01).
In like manner, other embodiment and proportioning of the present invention tested, effect is with embodiment 1.
Result shows: tested material has no adverse effects to weight of mice.
Known to the criterion of health food for alleviating physical strength fatigue according to " health food check and assessment technique standard " (2003 editions), compositions provided by the invention has the function of alleviating physical fatigue.
In sum: compositions avirulence provided by the invention, there is the function of enhancing immunity, alleviating physical fatigue.
Although, above use general explanation, the specific embodiment and test, the present invention is described in detail, on basis of the present invention, can make some modifications or improvements it, and this will be apparent to those skilled in the art.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, all belong to the scope of protection of present invention.
Claims (10)
1. a compositions for enhancing immunity, alleviating physical fatigue, it contains following composition: cervus elaphus linnaeus, Fructus Lycii extract, Radix Ophiopogonis extract, Ganoderma extract, Radix Panacis Quinquefolii extract.
2. compositions according to claim 1, it is characterized in that the composition that described compositions contains following weight portion: cervus elaphus linnaeus 1-4 part, Fructus Lycii extract 0.5-3 part, Radix Ophiopogonis extract 0.5-2 part, Ganoderma extract 0.5-2 part, Radix Panacis Quinquefolii extract 0.5-1.5 part.
3. compositions according to claim 1, it is characterized in that the composition that described compositions contains following weight portion: cervus elaphus linnaeus 1.1-3.3 part, Fructus Lycii extract 0.8-2.4 part, Radix Ophiopogonis extract 0.6-1.8 part, Ganoderma extract 0.55-1.65 part, Radix Panacis Quinquefolii extract 0.5-1.5 part.
4. compositions according to claim 1, is characterized in that, the composition that described compositions contains following weight portion: 2.2 parts of cervus elaphus linnaeuss, 1.6 parts of Fructus Lycii extracts, 1.2 parts of Radix Ophiopogonis extracts, 1.1 parts of Ganoderma extracts, 1 part of Radix Panacis Quinquefolii extract.
5. according to the compositions described in claim 1-4 any one, it is characterized in that, described Fructus Lycii extract refers to the water extract of Fructus Lycii, and wherein the content of crude polysaccharides is no less than 30.0%.
6. according to the compositions described in claim 1-4 any one, it is characterized in that, described Radix Ophiopogonis extract refers to the water extract of Radix Ophiopogonis, and the content of crude polysaccharides is no less than 3.0%.
7. according to the compositions described in claim 1-4 any one, it is characterized in that, described Ganoderma extract refers to the water extract of Ganoderma, and the content of crude polysaccharides is no less than 10.0%.
8. according to the compositions described in claim 1-4 any one, it is characterized in that, described Radix Panacis Quinquefolii extract refers to the ethanol extract of Radix Panacis Quinquefolii, and the content of total saponins is no less than 10.0%.
9. containing the preparation of the compositions described in claim 1-8 any one, it is characterized in that, said preparation is made up of compositions and pharmaceutically acceptable carrier.
10. the application of preparation in medicine or the health product of preparing enhancing immunity, alleviating physical fatigue described in compositions or claim 9 described in claim 1-8 any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410012306.9A CN103800661B (en) | 2014-01-10 | 2014-01-10 | A kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410012306.9A CN103800661B (en) | 2014-01-10 | 2014-01-10 | A kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103800661A true CN103800661A (en) | 2014-05-21 |
| CN103800661B CN103800661B (en) | 2016-07-13 |
Family
ID=50698356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410012306.9A Active CN103800661B (en) | 2014-01-10 | 2014-01-10 | A kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103800661B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104127577A (en) * | 2014-08-12 | 2014-11-05 | 安徽衡济堂灵芝产业开发有限公司 | Chinese medicine capsule for relieving physical fatigue and preparation method of Chinese medicine capsule |
| CN105341908A (en) * | 2015-11-05 | 2016-02-24 | 四川知本生物工程有限公司 | Functional health-care food capsule and preparation method thereof |
| CN105663394A (en) * | 2016-02-01 | 2016-06-15 | 孙爱华 | Chinese date healthcare product having effect of enhancing immunity as well as preparation method and application of healthcare product |
| CN106138440A (en) * | 2016-08-30 | 2016-11-23 | 张丽 | A kind of containing Lepidinm meyenii Walp and the compositions of Radix Rhodiolae and preparation method and purposes |
| CN106236804A (en) * | 2016-08-31 | 2016-12-21 | 山东万安药业有限公司 | A kind of Chinese medicine composition for improving body immunity |
| CN107307423A (en) * | 2017-07-12 | 2017-11-03 | 吉林青晨药业有限公司 | Product and preparation method with regulation enhancing body's immunity |
| CN107495350A (en) * | 2017-10-13 | 2017-12-22 | 延边韩工坊健康制品有限公司 | A kind of health food and preparation method with function of physical fatigue alleviation |
| CN108186879A (en) * | 2018-03-29 | 2018-06-22 | 山西正元盛邦制药有限公司 | A kind of alleviation physical fatigue Chinese medicine health-care composition and preparation method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1387911A (en) * | 2002-06-24 | 2003-01-01 | 李世臣 | Health wine for raising kidney function and immunity |
-
2014
- 2014-01-10 CN CN201410012306.9A patent/CN103800661B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1387911A (en) * | 2002-06-24 | 2003-01-01 | 李世臣 | Health wine for raising kidney function and immunity |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104127577A (en) * | 2014-08-12 | 2014-11-05 | 安徽衡济堂灵芝产业开发有限公司 | Chinese medicine capsule for relieving physical fatigue and preparation method of Chinese medicine capsule |
| CN105341908A (en) * | 2015-11-05 | 2016-02-24 | 四川知本生物工程有限公司 | Functional health-care food capsule and preparation method thereof |
| CN105341908B (en) * | 2015-11-05 | 2018-06-29 | 四川知本生物工程有限公司 | A kind of functional health-care food capsule and preparation method thereof |
| CN105663394A (en) * | 2016-02-01 | 2016-06-15 | 孙爱华 | Chinese date healthcare product having effect of enhancing immunity as well as preparation method and application of healthcare product |
| CN106138440A (en) * | 2016-08-30 | 2016-11-23 | 张丽 | A kind of containing Lepidinm meyenii Walp and the compositions of Radix Rhodiolae and preparation method and purposes |
| CN106138440B (en) * | 2016-08-30 | 2019-08-06 | 张丽 | A kind of composition containing maca and root of kirilow rhodiola and preparation method and purposes |
| CN106236804A (en) * | 2016-08-31 | 2016-12-21 | 山东万安药业有限公司 | A kind of Chinese medicine composition for improving body immunity |
| CN107307423A (en) * | 2017-07-12 | 2017-11-03 | 吉林青晨药业有限公司 | Product and preparation method with regulation enhancing body's immunity |
| CN107495350A (en) * | 2017-10-13 | 2017-12-22 | 延边韩工坊健康制品有限公司 | A kind of health food and preparation method with function of physical fatigue alleviation |
| CN108186879A (en) * | 2018-03-29 | 2018-06-22 | 山西正元盛邦制药有限公司 | A kind of alleviation physical fatigue Chinese medicine health-care composition and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103800661B (en) | 2016-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103800661B (en) | A kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation | |
| CN109674958A (en) | A kind of Chinese medicine composition and its preparation method and application with anti-trioxypurine | |
| CN112972547A (en) | Traditional Chinese medicine composition for treating qi-blood deficiency syndrome and preparation method and application thereof | |
| WO2021114586A1 (en) | Immune response-improving composition, preparation method and application thereof | |
| WO2022057499A1 (en) | Composition and preparation method for same | |
| CN108813610A (en) | A kind of saussurea involucrata composition and its application for improving immunity | |
| CN103432421B (en) | Medicine composition for improving immunity | |
| CN105535425B (en) | A kind of Chinese medicine composition with strengthen immunity effect and preparation method thereof and purposes | |
| CN101411375B (en) | Cold tea for preventing and treating coprostasis type sub-health and preparation method thereof | |
| CN101391004B (en) | Medicine composition for treating late-stage esophageal carcinoma | |
| CN106690201A (en) | Composition with immunity enhancing function and preparation method thereof | |
| CN104069194B (en) | A kind of Chinese medicine composition with antitumaous effect and its production and use | |
| CN111375035A (en) | Preparation and application of enteric-coated preparation for treating cervical spondylosis | |
| CN104352940B (en) | A kind of Chinese medicine composition for alleviating physical fatigue | |
| CN108126011B (en) | Pharmaceutical composition for auxiliary conditioning of patients undergoing tumor radiotherapy and chemotherapy and preparation method thereof | |
| CN102988602A (en) | Wolfberry and mushroom polysaccharide tablet | |
| CN110974903A (en) | Composition helpful for enhancing immunity and preparation method thereof | |
| CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae | |
| CN105770187A (en) | Health food capable of improving immunity and preparing method thereof | |
| CN111249421B (en) | Traditional Chinese medicine preparation for treating initial damp-heat exogenous fever as well as preparation method and application thereof | |
| CN113101331B (en) | Thyme herb tea and preparation method and application thereof | |
| CN112755137B (en) | Traditional Chinese medicine composition for treating mild and moderate knee osteoarthritis and application thereof | |
| CN104208213B (en) | A kind of Chinese-western medicine preparation treating chicken coccidiosis and preparation method thereof | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| CN105770474A (en) | Lupus erythematosus resisting drug for combined immunization and preparing method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |